Enhanced Neuroprotective Effects of Coadministration of @entity26249 with XXXX in Preclinical Model of @entity191 .

@entity3034 @entity935 @entity2041 @entity2359 @entity6172 @entity191 @entity26249 @entity26250 @entity35 @entity2955 @entity4149
Aim. In this study we examined the influence of @entity26249 ( @entity26250 ) on the neuroprotective effects of @entity2041 ( @entity6172 ) in the @entity2955 - ( @entity2955 ) lesioned @entity35 model of @entity191 ( @entity191 ). Methods. Levels in the redox system, @entity935 (DA) metabolism, dopaminergic neuronal survival, and apoptosis of the substantia nigra (SN) and striatum, as well as the rotational behavior of animals were examined after a 50-day administration of @entity6172 + @entity26250 (or @entity6172 ) and/or @entity3034 ( @entity3034 ) to @entity191 @entity35 . Ethics Committee of Huashan Hospital, Fudan University approved the protocol (number SYXK2009-0082). Results. Administration of @entity6172 or @entity26250 alone did not show any significant effects on the factors evaluated in the @entity191 @entity35 . However, in the @entity6172 + @entity26250 group, we observed markedly decreased oxidative damage, inhibition of DA metabolism and enhanced DA synthesis, increased @entity4149 hydroxylase- (TH-) immunopositive neuronal survival, and delayed apoptosis of dopaminergic neurons in the SN. Animal rotational behavior was improved in the @entity6172 + @entity26250 group. Additionally, coadministration of @entity6172 + @entity26250 appeared to offset the possible oxidative @entity2359 induced by @entity3034 . Conclusion. In this study, we demonstrated that @entity26249 allowed occurrence of the neuroprotective effect of @entity2041 probably due to inhibition of P-glycoprotein on @entity2955 -lesioned @entity35 models of @entity191 , including @entity35 undergoing long-term @entity3034 treatment.
